| abstract |
The present invention relates to an HDM2-p53 interaction inhibitor (S) -5- (5-chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl) -6- (4-chloro-). Phenyl) -2- (2,4-dimethoxy-pyrimidine-5-yl) -1-isopropyl-5,6-dihydro-1H-pyrrolo [3,4-d] imidazole-4-one [HDM201] and TIM -3 Regarding combination with an anti-TIM-3 antibody molecule as an inhibitor. The present invention further relates to the use of the combination in the treatment of cancer, especially hematological malignancies. The present invention further relates to dose and dosing regimens associated with this combination cancer treatment. |